Partnerships
We are interested in exploring partnerships for our programs on a global or regional basis. For additional information about our products or to inquire about partnering opportunities, please reach out to us.
RX-5902 is a potential first-in-class small molecule inhibitor of phosphorylated-p68, which is selectively over-expressed in cancer cells and modulates the activity of the β-catenin/Wnt pathway which is involved in cancer cell growth and proliferation, oncogene expression and in the immune response to cancer.
Phosphorylated p68, which is highly expressed in cancer cells, but not in normal cells, results in up-regulation of cancer-related genes and a subsequent proliferation of cancer cells and tumor growth. RX-5902 selectively blocks the interaction of phosphorylated p68 with beta-catenin, thereby decreasing the proliferation or growth of cancer cells in preclinical models. Apart from its direct antitumor effects, RX-5902 is immunomodulatory and multiple preclinical models suggest that RX-5902 enhances the efficacy of immunotherapy. Rexahn has evaluated RX-5902 in a Phase 1 dose escalation study in patients with a diverse range of metastatic, treatment-refractory solid tumors, including breast, ovarian, colorectal, and neuroendocrine tumors. In February 2017, Rexahn initiated a Phase 2a clinical study of RX-5902 monotherapy in patients with metastatic triple negative breast cancer (TNBC). In August 2018, we announced a collaboration with Merck to evaluate RX-5902 in combination with Keytruda® in TNBC.
Product Candidate | Indication | Development Stage | Anticipated Milestones | |||||
---|---|---|---|---|---|---|---|---|
Preclinical | Phase 1 | Phase 2 | Phase 3 | Regulatory Approval | ||||
Retina-Focused Development |
||||||||
APX3330 Oral Pill | Diabetic Retinopathy (DR)/ Macular Edema (DME) |
Preclinical complete
|
Phase 1 complete
|
Phase 2 in progress
Completed Trial
SPA Submission
|
Phase 3 not started
|
Regulatory Approval not started
|
EOP2 Mtg October 2023 Special Protocol Assessment (SPA) Submission |
|
APX2009 Local Delivery | Retina |
Preclinical in progress
|
Phase 1 not started
|
Phase 2 not started
|
Phase 3 not started
|
Regulatory Approval not started
|
Select retinal drug delivery technology |
|
APX2014 Local Delivery | Retina |
Preclinical in progress
|
Phase 1 not started
|
Phase 2 not started
|
Phase 3 not started
|
Regulatory Approval not started
|
Select retinal drug delivery technology |
|
Refractive-Focused Development |
||||||||
Phentolamine Ophthalmic Solution 0.75% Eye Drop | Pharmacologically-Induced Mydriasis |
Preclinical complete
|
Phase 1 complete
|
Phase 2 complete
|
Phase 3 complete
|
Regulatory Approval in progress
partnered with Viatris
|
APPROVED RYZUMVI™ (phentolamine ophthalmic solution) 0.75% Sept 2023 |
|
Phentolamine Ophthalmic Solution 0.75% + Low-Dose 0.4% Pilocarpine Eye Drops | Presbyopia |
Preclinical complete
|
Phase 1 complete
|
Phase 2 complete
|
Phase 3 in progress
partnered with Viatris
Phase 3 Initiated
|
Regulatory Approval not started
|
VEGA-2 Phase 3 Topline Data Q4 2023 |
|
Phentolamine Ophthalmic Solution 0.75% Eye Drop | Dim Light or Night Vision Disturbances (NVD) |
Preclinical complete
|
Phase 1 complete
|
Phase 2 complete
|
Phase 3 in progress
partnered with Viatris
|
Regulatory Approval not started
|
SPA Submitted LYNX-2 2nd Phase 3 trial (n=150+) |
Of breast cancer is triple-negative, testing negative for both hormone receptors and HER2.1
Women ages 50-54 will be diagnosed with breast cancer in the next year.1
Chance of Diagnosis of breast cancer within the lifetime of a woman living in the US.1
1 American Cancer Society